<DOC>
	<DOCNO>NCT00299494</DOCNO>
	<brief_summary>The purpose study determine tolerability , initial safety profile maximum tolerate dose , obtain preliminary information antitumor activity inotuzumab ozogamicin [ CMC-544 ] combination rituximab subject follicular , diffuse large B-Cell , mantle cell NHL .</brief_summary>
	<brief_title>Study Evaluating Inotuzumab Ozogamicin CMC-544 Administered In Combination With Rituximab In Subjects With Non-Hodgkin 's Lymphoma ( NHL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Subjects CD20 CD22positive , follicular diffuse large Bcell NHL respond progress 1 2 prior therapy ; subject CD20 CD22positive intermediate/aggressive NHL ( diffuse large Bcell , mantle cell , transform follicular follicular grade 3b NHL ) respond progressed 1 prior therapy refractory previous rituximab contain therapy . Prior therapy must contain least one course rituximab therapy , single agent combination . Measurable disease . Subjects candidate potentially curative therapy . Subjects must receive previous radioimmunotherapy . Subjects undergone prior bone marrow transplantation within last 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>NHL</keyword>
</DOC>